ITM Isotope Technologies Munich SE's August 28, 2026 PDUFA target action date for 177Lu-edotreotide (ITM-11, a synthetic somatostatin-analog peptide-radioconjugate for gastroenteropancreatic neuroendocrine tumors) passed without an FDA approval decision, following the August 7, 2026 Complete Response Letter that cited Chemistry, Manufacturing, and Controls items and unresolved conditions at a third-party commercial manufacturing facility as the sole basis for the refusal. The FDA explicitly did not raise clinical or nonclinical safety or efficacy concerns, and did not request additional clinical data. ITM has stated it plans to resubmit the NDA once the manufacturing and facility items are addressed. The Phase 3 COMPETE trial (309 patients, first- or second-line inoperable progressive Grade 1 or Grade 2 GEP-NETs) had met its primary endpoint with a significant progression-free survival benefit over everolimus and a significantly higher objective response rate. The CRL is the second on the ITM-11 program and delays direct commercial competition with Novartis Lutathera (177Lu-DOTATATE, the incumbent peptide-radioconjugate for GEP-NETs).
ITM Isotope Technologies Munich SE received a Complete Response Letter (CRL) from the US FDA on August 7, 2026, disclosed August 10-11, for 177Lu-edotreotide (ITM-11), a somatostatin analog radioligand peptide therapeutic under investigation for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CRL cited chemistry, manufacturing, and controls (CMC) and third-party commercial manufacturing facility items that must be addressed before the application can be approved. Notably, the FDA did not identify any concerns regarding the clinical data package, nonclinical data, or safety profile of ITM-11. The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide compared to everolimus (an oral mTOR inhibitor targeted molecular therapy) in patients with inoperable, progressive Grade 1 or Grade 2 GEP-NETs. ITM-11 is a peptide radioligand therapy: a somatostatin receptor 2 (SSTR2)-targeting peptide chelated to the beta-emitting radionuclide lutetium-177 to deliver targeted radiation to SSTR2-expressing neuroendocrine tumor cells. The category is anchored commercially by Novartis's Lutathera (177Lu-dotatate) and Pluvicto (177Lu-vipivotide tetraxetan, PSMA-targeting for prostate cancer). ITM intends to resubmit and complete the NDA review process. The manufacturing-focused CRL is a substantially better outcome than a clinical-data CRL: resolution timelines for CMC-only CRLs typically run 4-8 months versus 12+ months for data-driven CRLs, and the fundamental commercial thesis remains intact.